Clinical Trial Update: A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

A randomized Phase 2 trial in first-line advanced renal cell carcinoma compares nivolumab with ipilimumab plus relatlimab versus nivolumab with ipilimumab, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Ipilimumab (Yervoy) (ipilimumab)
• Relatlimab (relatlimab)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Carcinoma, Clear Cell | Phase 2 | Status: RECRUITING